ALK and non-small cell lung carcinoma: Patients with metastatic non-small cell lung cancer are routinely tested for EGFR mutations and rearrangements of the gene encoding the ALK tyrosine kinase receptor/anaplastic lymphoma kinase (ALK) to guide treatment.